Lv33
310 积分 2021-01-20 加入
Efficacy and Safety of Zimlovisertib, Ritlecitinib, and Tofacitinib, Alone and in Combination, in Patients With Moderate to Severe Rheumatoid Arthritis and an Inadequate Response to Methotrexate
20小时前
已完结
Expanding the reach of molecular glue degraders
1天前
已完结
The kinase IRAK4 promotes endosomal TLR and immune complex signaling in B cells and plasmacytoid dendritic cells
4天前
已完结
IRAK4 inhibition dampens pathogenic processes driving inflammatory skin diseases
4天前
已完结
IRAK4: potential therapeutic target for airway disease exacerbations
4天前
已完结
Discovery of APH02174 as a Highly Selective and Orally Bioavailable IRAK4 Degrader for the Treatment of Inflammatory Diseases
4天前
已完结
The targeted protein degradation landscape
12天前
已完结
Durvalumab plus Cetuximab in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: An Open-label, Nonrandomized, Phase II Clinical Trial
14天前
已完结
Discovery of BIO-8169─A Highly Potent, Selective, and Brain-Penetrant IRAK4 Inhibitor for the Treatment of Neuroinflammation
18天前
已完结
Discovery of Edecesertib (GS-5718): A Potent, Selective Inhibitor of IRAK4
18天前
已完结
皖公网安备34019202002308
